Top Markets
#1 QuantixAI QuantixAI +102.83%
#2 MetaDAO MetaDAO +25.19%
#3 龙虾 (Lobster) 龙虾 (Lobster) +23.59%
#4 Pons Pons +23.51%
#5 Rain Rain +21.62%
#6 Bedrock Bedrock +21.46%
#7 Ontology Gas Ontology Gas +20.86%
#8 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +20.37%
#9 Wrapped STX (Velar) Wrapped STX (Velar) +19.56%
#10 SPX6900 SPX6900 +18.54%
Coin of the day
QuantixAI QuantixAI
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Grifols, S.A. Grifols, S.A.

Grifols, S.A.

GRF
Rang in Aktien #2542
Grifols, S.A., a Spanish company established in 1940 and headquartered in... Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from plasma. The company operates through several key divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies, among others. The Bioscience division is dedicated to the research, development, production, and commercialization of plasma-derived medicines and other cutting-edge solutions. These are designed to treat individuals suffering from chronic, rare, widespread, and life-threatening medical conditions, with its product portfolio including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies a range of non-biological pharmaceutical products, clinical nutrition items, intravenous (IV) therapy solutions, and various medical devices and supplies. Grifols' Diagnostic division develops and markets advanced diagnostic tools that support healthcare professionals across the entire patient care continuum, from prevention and screening to accurate diagnosis, prognosis, and ongoing disease and treatment monitoring. Finally, the Bio Supplies division provides essential biological materials for life-science research, clinical trials, and the manufacturing of both pharmaceutical and diagnostic goods. Collectively, Grifols' offerings enable healthcare providers to effectively diagnose and treat a broad spectrum of medical conditions, such as hemophilia, various immune deficiencies, and infectious diseases. Its diverse client base includes public and private sector organizations, wholesalers, distributors, group purchasing organizations (GPOs), blood banks, hospitals, care institutions, and national health systems. Grifols also maintains a technology collaboration agreement with Mondragon.
Aktienkurs
$11.91
Marktkapitalisierung
$8.11B
Veränderung (1 Tag)
1.67%
Veränderung (1 Jahr)
-16.23%
Land
ES
Handel Grifols, S.A. (GRF)

Kategorie

Healthcare
Gewinn für Grifols, S.A. (GRF)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von Grifols, S.A. betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Grifols, S.A. von 2026 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
Nicht genügend Daten für die angegebenen Daten.
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
$33.59B -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
$25.20B -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
$8.70B -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
$21.39B -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
$5.95B -
US